Status:
TERMINATED
Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
Lead Sponsor:
UConn Health
Collaborating Sponsors:
United States Department of Defense
Conditions:
Ischemia
Coronary Disease
Eligibility:
All Genders
18+ years
Brief Summary
Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosin...
Detailed Description
Objectives: The overall goal of this proposal is to develop methods to achieve heart and vascular protection from ischemia and thus improve soldier's performance in adverse environment. The major hyp...
Eligibility Criteria
Inclusion
- Subjects with or without coronary artery disease undergoing a Persantine nuclear stress test
Exclusion
- Oral persantine use within 24 hours
- Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
- Active asthma or bronchospasm
- Those with end-stage liver disease such as cirrhosis or active hepatitis such as \> 5 fold liver enzyme elevation will not be included
- Anemia (Hct \< 30)
- Myocardial infarction within 30 days
- Severe left ventricular dysfunction (EF \< 30%)
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
221 Patients enrolled
Trial Details
Trial ID
NCT00760708
Start Date
September 1 2005
End Date
December 1 2011
Last Update
May 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Connecticut Health Center
Farmington, Connecticut, United States, 06032